Marketing Rights of TMX-67 in China and Hong Kong
—Novel Drug for Chronic Management of Hyperuricemia in Gout Patients—
Teijin Pharma Limited (“Teijin Pharma”) and Astellas Pharma Inc. announced today that they have entered into an exclusive distributorship agreement between Teijin Pharma and two subsidiaries of Astellas Pharma Inc., namely Astellas Pharma China, Inc(“Astellas China”). and Astellas Pharma Hong Kong Co., Ltd.(“Astellas Hong Kong”), regarding the marketing of TMX-67 (generic name: febuxostat) in China and Hong Kong respectively. TMX-67 is a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout.

In China, Teijin Pharma and Astellas China will co-develop and manage approval process of TMX-67. Sales in the Chinese market will be handled by Astellas China after its commercial launch, which is targeted at 2014. Teijin Pharma also holds co-promotion rights in Shanghai. In Hong Kong, Astellas Hong Kong will manage the approval process and handle sales after its commercial launch targeted at 2011. Teijin Pharma will supply the finished product and receive an upfront licensing fee as well as commercial milestone payments.

TMX-67, developed by Teijin Pharma after intensive research, is an oral, once-daily, highly potent, non-purine selective inhibitor of xanthine oxidase. The current leading medication, allopurinol, was developed nearly 40 years ago, so a new drug that provides more options for the treatment of gout and hyperuricemia has long been sought. TMX-67 has proven therapeutic superiority to allopurinol and above all is well tolerated by patients suffering from a mild and moderate renal impairment.

Teijin Pharma hopes to contribute to the quality of life in gout patients in China and Hong Kong, as well as other areas around the globe, by continuing to pursue collaborative efforts to broaden TMX-67's global availability.

Astellas has already established its business platform in Asia. Particularly the sales of Astellas China is currently growing over 10%. Astellas expects to further expand the business in China and Hong Kong by entering TMX-67 into the market.

About Teijin Phrama Limited
Teijin Pharma Limited, the core company of Teijin Group's medical and pharmaceuticals business, focuses on three key therapeutic areas: respiratory, bone/joint, and cardiovascular/metabolic diseases. Teijin Pharma has strong marketing positions, particularly in the respiratory and bone/joint areas, with pharmaceutical products as well as a home healthcare business, including home oxygen therapy. Teijin Pharma continues to enhance its presence worldwide through in-house R&D as well as in-licensing and out-licensing activities. For more information, visit www.teijin-pharma.co.jp/english/

About the Teijin Group
Based in Tokyo and Osaka, Japan, Teijin is a global technology-driven group operating in five main fields: synthetic fibers (aramid fibers, carbon fibers and polyester fibers); films and plastics; pharmaceuticals and home health care; trading and retail; and IT and new products. Teijin Limited, the holding company for the Teijin Group, is listed on the Tokyo and Osaka stock exchanges. The group had consolidated sales of USD 10.5 billion (JPY 943.4 billion, USD 1=JPY 90) in fiscal 2008 and employs 19,453 people worldwide, with 169 companies around the world.


About Astellas
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 14,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology & Infectious Diseases, Neuroscience, DM complications & Metabolic Diseases and Oncology. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com/en